Welcome to our dedicated page for Indaptus Therapeutics SEC filings (Ticker: INDP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Indaptus Therapeutics, Inc. (Nasdaq: INDP) SEC filings page on Stock Titan provides structured access to the company’s regulatory documents as filed with the U.S. Securities and Exchange Commission. As a clinical-stage biotechnology issuer incorporated in Delaware and listed on the Nasdaq Capital Market, Indaptus uses its SEC reports to describe the development of its Decoy bacterial immunotherapy platform, its clinical programs, and its financing and corporate activities.
Through Forms 10-K and 10-Q, investors can review detailed discussions of Indaptus’ business, including its focus on Decoy20 and related product candidates for cancer and viral infections, pre-clinical data summaries, risk factors, and management’s analysis of research and development and general and administrative expenses. Current reports on Form 8-K capture material events such as the launch and progression of the INDP-D101 clinical trial, reverse stock split implementation, private placements of convertible promissory notes and warrants, standby equity purchase agreements, preferred stock financings, and changes to the board of directors and executive leadership.
Registration statements on Form S-1 and amendments (S-1/A) outline the terms of securities offerings, including common stock, pre-funded warrants, common warrants and placement agent warrants, as well as estimated offering expenses and recent sales of unregistered securities. These filings also confirm Indaptus’ status as a smaller reporting company and non-accelerated filer and provide information on its incorporation and principal executive offices.
On Stock Titan, users can access these filings alongside AI-powered summaries that highlight key points such as capital structure changes, potential dilution from convertible instruments and warrants, and the implications of preferred stock transactions. The platform also surfaces insider-related disclosures and board changes reported in 8-Ks, helping readers quickly identify governance developments. Real-time updates from EDGAR ensure that new Indaptus filings, from quarterly earnings reports to material event disclosures, are added promptly, while AI-generated explanations help interpret complex prospectus language, financing terms and clinical program descriptions within the filings.
Indaptus Therapeutics reported a change in control tied to earlier issuances of Series AA and Series AAA Convertible Preferred Stock. David Lazar had purchased 300,000 Series AA and 700,000 Series AAA shares, which are convertible into a combined 111,000,000 shares of common stock. He has now sold all 700,000 Series AAA shares and rights to 196,800 Series AA shares to five Purchasers for an aggregate $11.2 million. Based on full conversion of all Preferred Stock and a total of 113,242,324 common shares outstanding on that basis, the Purchasers together would beneficially own about 96.20% of the common stock, while Lazar would hold about 1.82%. Several directors, including co-CEO Jeffrey Meckler, resigned, and Lazar stepped down as co-CEO and Chairman while remaining on the board. The board appointed Junyi Dai as Chairman effective March 18, 2026 and as Chief Executive Officer effective at closing of the March 2026 share sale.
Indaptus Therapeutics’ major shareholder David E. Lazar has sharply reduced his economic stake and stepped down as co‑Chief Executive Officer while remaining on the Board. He entered a March 2026 securities purchase agreement to sell 700,000 shares of Series AAA Preferred Stock and 196,800 shares of Series AA Preferred Stock for an aggregate $11,200,000.
These preferred shares are convertible into a total of 108,936,000 common shares. After closing on March 23, 2026, Lazar retains 103,200 Series AA Preferred shares, convertible into 2,064,000 common shares. Based on 2,242,324 common shares outstanding as of March 16, 2026 plus his remaining convertibles, the filing reports beneficial ownership of approximately 47.93%, which would drop to about 1.82% after other purchasers convert their preferred stock.
Indaptus Therapeutics director David E. Lazar sold a large block of the company’s convertible preferred stock. On March 23, 2026, he completed a Securities Purchase Agreement under which he sold all 700,000 shares of Series AAA Preferred Stock, which were convertible into 105,000,000 shares of common stock, and 196,800 shares of Series AA Preferred Stock, which were convertible into 3,936,000 shares of common stock. Following this transaction, he retained 103,200 shares of Series AA Preferred Stock, convertible into 2,064,000 shares of common stock. Both the Series AA and Series AAA Preferred Stock are perpetual and convertible at the holder’s option for no additional consideration.
Indaptus Therapeutics reports a transformative year marked by a recapitalization, governance changes and a halt to clinical development. On December 22, 2025 it sold 300,000 Series AA and 700,000 Series AAA preferred shares to David E. Lazar for $6.0 million, each share priced at $6.00. These series are convertible into a combined 111,000,000 common shares, and Mr. Lazar is now the beneficial owner of about 96.4% of the company’s common stock on an as-converted, fully diluted basis.
Stockholders approved a large increase in authorized common shares to 1,000,000,000, a reverse stock split range, and board changes that installed multiple Lazar designees. The company repriced roughly 1.68 million warrants to an exercise price of $1.75 per share and used ATM sales, a $5.7 million convertible note, equity lines and several 2024–2025 equity/warrant financings to raise cash.
Indaptus, a clinical-stage immunotherapy developer, discontinued enrollment in its Decoy20 monotherapy and combination trials and has no current plans to start new clinical studies. It discloses substantial doubt about its ability to continue as a going concern and is evaluating a strategic transaction to invest in or acquire a target company.
Indaptus Therapeutics Inc. investor David E. Lazar has disclosed effective control of the company, reporting beneficial ownership of 111,000,000 shares of common stock, or about 98% of the class, through convertible preferred stock.
Under a Securities Purchase Agreement dated December 22, 2025, Lazar agreed to buy 300,000 shares of Series AA Preferred Stock, convertible into 6 million common shares for $1.8 million, and 700,000 shares of Series AAA Preferred Stock, convertible into 105 million common shares for $4.2 million, for total consideration of $6 million. Stockholders approved the necessary share increase and conversion on February 26, 2026.
Following this deal, Lazar became Co-Chief Executive Officer and a director, and is expected to serve as Chairman of the Board. He also obtained the right to recommend up to three additional director nominees at a future stockholder meeting and has participation rights in future Indaptus financing transactions.
Jabbour Jerome D reported acquisition or exercise transactions in this Form 4 filing.
Indaptus Therapeutics director receives stock option grant. Indaptus Therapeutics, Inc. granted director Jerome D. Jabbour options to buy 25,000 shares of common stock under its non-employee director compensation program. These options vest over three years in equal quarterly installments, conditioned on his continued service on the board.
Indaptus Therapeutics reports that stockholders approved a set of proposals that enables a change in control, large potential share issuance and structural changes to its charter and bylaws.
Following a prior preferred stock investment by David E. Lazar, stockholders approved issuing common shares upon conversion of 300,000 Series AA and 700,000 Series AAA Convertible Preferred Stock. After the related charter amendment filing, these preferred shares are convertible at Mr. Lazar’s option into 111.0 million common shares, representing about 96.4% of common stock on a fully diluted basis.
Stockholders also authorized the board to implement up to two reverse stock splits in a 1‑for‑2 to 1‑for‑199 range, approved increasing authorized common shares to 1,000,000,000 and allowed stockholder action by written consent. Two directors, Jerome Jabbour and Matthew McMurdo, were elected, giving Mr. Lazar’s nominees a majority of the nine‑member board.
Indaptus Therapeutics, Inc. filed an initial insider ownership report for board member Jerome D. Jabbour on Form 3. This filing establishes his status as a director subject to insider reporting rules. The report does not list any buy, sell, or other share transactions.
Indaptus Therapeutics, Inc. director Matthew Charles McMurdo reported his initial ownership of the company’s common stock. He holds 25,000 shares of common stock directly, as shown in this initial statement of beneficial ownership.
Indaptus Therapeutics Co-Chief Executive Officer and director Jeffrey Meckler reported derivative warrant transactions tied to a board-approved repricing. On February 11, 2026, previously held warrants were disposed of back to the company and replacement warrants were acquired on a direct ownership basis.
The transactions cover several warrant series exercisable for common stock, with the board unilaterally reducing the per-share exercise price of all affected warrants to $1.75 while leaving all other terms unchanged. Following the dispositions and matching acquisitions, Meckler directly holds new warrants for 3,033, 1,519, and 12,136 underlying shares at the revised exercise price.
The filing also notes that on June 26, 2025, Indaptus implemented a 1-for-28 reverse stock split of its common stock, and all warrant amounts in the report reflect this adjustment.